» Articles » PMID: 39436583

Preventive Effect of Imperatorin Against Doxorubicin-induced Cardiotoxicity Through Suppression of NLRP3 Inflammasome Activation

Overview
Journal J Nat Med
Publisher Springer
Date 2024 Oct 22
PMID 39436583
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiotoxicity is one of the major obstacles to anthracycline chemotherapy. Anthracycline cardiotoxicity is closely associated with inflammation. Imperatorin (IMP), a furocoumarin ingredient extracted from Angelica dahurica, might have potential activity in preventing anthracycline cardiotoxicity due to its anti-cancer, anti-inflammatory, anti-oxidant, cardioprotective properties. This study aims to reveal the effect of IMP on doxorubicin (DOX)-induced cardiotoxicity and its underlying mechanism. We established a rat model of DOX-induced cardiotoxicity by intraperitoneal injection with DOX (1.25 mg/kg twice weekly for 6 weeks), and found that both IMP (25 mg/kg and 12.5 mg/kg) and dexrazoxane 12.5 mg/kg relieved DOX-induced reductions in heart weight, change in cardiac histopathology, and elevated serum levels of LDH, AST and CK-MB. Moreover, DOX upregulated mRNA levels of NLRP3, CASP1, GSDMD, ASC, IL-1β and IL-18, elevated protein expressions of NLRP3, ASC, GSDMD-FL, GSDMD-N, pro‑caspase‑1, caspase‑1 p20, pro‑IL‑1β and IL‑1β in heart tissues, as well as increased serum levels of pro-inflammatory cytokines including IL-1β and IL-18, however both of IMP and dexrazoxane suppressed these alterations. In addition, we carried out neonatal rat cardiomyocytes experiments to confirm the results of the in vivo study. Consistently, pretreatment with IMP 25 µg/mL relieved DOX (1 μg/mL)-induced cardiomyocytes injury, including decreased cell viability and reduced supernatant LDH. IMP inhibited DOX-induced activation of NLRP3 inflammasome in cardiomyocytes. In conclusion, IMP had a protective effect against DOX-induced cardiotoxicity via repressing the activation of NLRP3 inflammasome. These findings suggest that IMP may be a promising alternative or adjunctive drug for the prevention of anthracycline cardiotoxicity.

References
1.
Saleh Y, Abdelkarim O, Herzallah K, Abela G . Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Fail Rev. 2020; 26(5):1159-1173. DOI: 10.1007/s10741-020-09968-2. View

2.
Bernstein D . Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?. Circ Res. 2018; 122(2):188-190. PMC: 5776743. DOI: 10.1161/CIRCRESAHA.117.312395. View

3.
Yang X, Liu N, Li X, Yang Y, Wang X, Li L . A Review on the Effect of Traditional Chinese Medicine Against Anthracycline-Induced Cardiac Toxicity. Front Pharmacol. 2018; 9:444. PMC: 5963334. DOI: 10.3389/fphar.2018.00444. View

4.
Wang Z, Qi F, Cui Y, Zhao L, Sun X, Tang W . An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. Biosci Trends. 2018; 12(3):220-239. DOI: 10.5582/bst.2018.01144. View

5.
Nasser M, Zhu S, Hu H, Huang H, Guo M, Zhu P . Effects of imperatorin in the cardiovascular system and cancer. Biomed Pharmacother. 2019; 120:109401. DOI: 10.1016/j.biopha.2019.109401. View